Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
ApexOnco Front Page
Recent articles
The company pays $2.5bn for Day One and its approved drug Ojemda.
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
So who else could be interested in the oestrogen degrader?
A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
The recently unveiled conjugate DS3610a is to start phase 1.
After menin, the company tries again with farnesyl transferase.
The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
